Results 61 to 70 of about 14,165 (152)

Multifacet Roles of Cellular Senescence in Cancer: Mechanisms and Therapeutic Implications

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Cellular senescence shapes tumor progression through both antitumor and protumor mechanisms. Senescence triggered by telomere shortening restricts malignant transformation and limits tumor cell proliferation, while the senescence‐associated secretory phenotype (SASP) secretion enhances antitumor immunity by activating cytotoxic T cells.
Huajie Mao, Wanning Liu, Yuanyuan Su, Yuxuan Ma, Xiaodi Zhao, Yuanyuan Lu   +5 more
wiley   +1 more source

The Evolution of Pneumocystis jirovecii Pneumonia Prophylaxis for Pediatric Patients With Extracranial Solid Tumors: A Review of Historical Insights and Future Directions

Pediatric Blood &Cancer, Volume 73, Issue 3, March 2026.
ABSTRACT Pneumocystis jirovecii pneumonia (PJP) remains a modern‐day complication for pediatric patients receiving treatment for extracranial solid tumors (ST), highlighting the need for reconsideration of our current approach toward PJP prophylaxis. This critical review aims to evaluate both universal and risk‐stratified approaches to PJP prophylaxis ...
Kriti Kumar, Denise M. Connolly, Ellen Kellington, Elyse Zelunka, Karla Kerrigan, Furqan Shaikh, Paul C. Nathan, Meredith S. Irwin, Sarah Cohen‐Gogo   +8 more
wiley   +1 more source

Quercetin inhibits the epithelial-mesenchymal transition and reverses CDK4/6 inhibitor resistance in breast cancer by regulating circHIAT1/miR-19a-3p/CADM2 axis.

PLoS ONE
Breast cancer (BC) cells have a high risk of metastasis due to epithelial-mesenchymal transition (EMT). Palbociclib (CDK4/6 inhibitor) is an approved drug for BC treatment.
Xiaogang Li, Chao Niu, Guoqiang Yi, Yuan Zhang, Wendi Jin, Zhiping Zhang, Wanfu Zhang, Bo Li   +7 more
doaj   +1 more source

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Breast Cancer Research, 2019
Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens.
Lorenzo Rossi, Chiara Biagioni, Amelia McCartney, Ilenia Migliaccio, Giuseppe Curigliano, Giuseppina Sanna, Erica Moretti, Alessandro M. Minisini, Saverio Cinieri, Carlo Tondini, Grazia Arpino, Antonio Bernardo, Angelo Martignetti, Emanuela Risi, Marta Pestrin, Luca Boni, Matteo Benelli, Laura Biganzoli, Angelo Di Leo, Luca Malorni   +19 more
doaj   +1 more source

Role of palbociclib in the treatment of hormone receptor-positive HER2-negative metastatic breast cancer. Generalizing results of randomized trials and real clinical practice

Медицинский совет, 2019
Palbociclib is the first-in-class drug of CDK 4/6 inhibitors group. The use of palbociclib in combination with endocrinotherapy (ET) opens up new possibilities for the treatment of metastatic hormone receptor-positive (HRP+) HER2-negative (HER2-) breast ...
L. G. Zhukova, E. I. Khatkova, P. S. Feoklistova, K. S. Grechukhina, S. A. Smolin, E. A. Arutyunyan, E. M. Kolyago   +6 more
doaj   +1 more source

Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion

Experimental Hematology & Oncology
Background Mantle cell lymphoma (MCL) is a chronically relapsing malignancy with deregulated cell cycle progression. We analyzed efficacy, mode of action, and predictive markers of susceptibility to palbociclib, an approved CDK 4/6 inhibitor, and its ...
Diana Malarikova, Radek Jorda, Kristyna Kupcova, Jana Senavova, Alexandra Dolnikova, Eva Pokorna, Dmitry Kazantsev, Kristina Nozickova, Dana Sovilj, Celine Bellanger, David Chiron, Ladislav Andera, Vladimir Krystof, Miroslav Strnad, Karel Helman, Magdalena Klanova, Marek Trneny, Ondrej Havranek, Pavel Klener   +18 more
doaj   +1 more source

Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study

Journal of Global Oncology, 2019
PURPOSE: In PALOMA-2, palbociclib plus letrozole significantly improved progression-free survival (PFS) as initial treatment of estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer.
Seock-Ah Im, Hirofumi Mukai, In Hae Park, Norikazu Masuda, Chikako Shimizu, Sung-Bae Kim, Young-Hyuck Im, Shoichiro Ohtani, Cynthia Huang Bartlett, Dongrui R. Lu, Shrividya Iyer, Yuko Mori, Ave Mori, Eric Gauthier, Richard S. Finn, Masakazu Toi   +15 more
doaj   +1 more source

TMEM45A enhances palbociclib resistance and cellular glycolysis by activating AKT/mTOR signaling pathway in HR+ breast cancer

Cell Death Discovery
Palbociclib, a CDK4/6 inhibitor, plays a crucial role in the treatment of HR+ breast cancer. However, resistance to palbociclib is a significant concern that merits further investigation.
Cui Chen, Zehong Chen, Jinze Zhao, Xinyun Wen, Hanming Yao, Zijin Weng, Huiping Xiong, Zongheng Zheng, Juekun Wu   +8 more
doaj   +1 more source

Population Pharmacokinetic and Pharmacodynamic Study of Palbociclib in Children and Young Adults with Recurrent, Progressive, or Refractory Brain Tumors

Pharmaceutics
Background/Objectives: Palbociclib, an oral CDK 4/6 inhibitor, was evaluated in a Pediatric Brain Tumor Consortium (PBTC) phase 1 (NCT02255461; PBTC-042) study to treat children and young adults with recurrent, progressive, or refractory brain tumors ...
John C. Panetta, Nicholas S. Selvo, David Van Mater, Clinton F. Stewart   +3 more
doaj   +1 more source

Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer

Breast Cancer Research
Background Breast cancers treated with aromatase inhibitors (AIs) can develop AI resistance, which is often driven by estrogen receptor-alpha (ERα/ESR1) activating mutations, as well as by ER-independent signaling pathways.
Muriel Lainé, Marianne E Greene, Justyna D Kurleto, Grazyna Bozek, Tiffany Leng, Rosemary J Huggins, Barry S Komm, Geoffrey L Greene   +7 more
doaj   +1 more source